| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1770 |
| Trial ID | NCT03262298 |
| Disease | Lymphoma | Leukemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies |
| Year | 2017 |
| Country | China |
| Company sponsor | Affiliated Hospital to Academy of Military Medical Sciences |
| Other ID(s) | 307-B-22-CAR-T |
| Cohort 1 | |||||||
|
|||||||